Europäische Union - Griechisch - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Europäische Union - Griechisch - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - Λευχαιμία, λεμφοκυτταρική, χρόνια, Β-κυτταρική - Αντινεοπλασματικοί παράγοντες - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Europäische Union - Griechisch - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - Πρωτοπλαστικά νεοπλάσματα - Αντινεοπλασματικοί παράγοντες - Θεραπεία μεταστατικού ορθοκολικού καρκίνου (mcrc).

Europäische Union - Griechisch - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Europäische Union - Griechisch - EMA (European Medicines Agency)

celgene europe ltd. - romεμπεψίνη - Λέμφωμα, μη-hodgkin - Αντινεοπλασματικοί παράγοντες - θεραπεία των περιφερικών Τ-κυττάρων λέμφωμα (ptcl),.

Europäische Union - Griechisch - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - Λευχαιμία, μυελοειδής, οξεία - Αντινεοπλασματικοί παράγοντες - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Europäische Union - Griechisch - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - Αντινεοπλασματικοί παράγοντες - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Europäische Union - Griechisch - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Griechenland - Griechisch - Εθνικός Οργανισμός Φαρμάκων

pharma mar s.a., spain avda de los reyes 1,, poligono industrial la mina, - lurbinectedin - ly.p.iv.in (ΕΝΕΣΙΜΟ ΛΥΟΦΙΛΟ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ) - 4mg/vial - lurbinectedin 4mg - lurbinectedin

Griechenland - Griechisch - Εθνικός Οργανισμός Φαρμάκων

eisai gmbh, frankfurt am main, germany edmund-rumpler-straße 3, 60549 frankfurt am main - eribulin mesylate - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 0,44mg/ml (0,88mg/2ml) - eribulin mesylate 0,44mg - eribulin